APA

Yahi N., Fantini J., Baghdiguian S., Mabrouk K., Tamalet C., Rochat H., Van Rietschoten J. & Sabatier J. M. (19950629). SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. : Proceedings of the National Academy of Sciences of the United States of America.

Chicago

Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J and Sabatier J M. 19950629. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. : Proceedings of the National Academy of Sciences of the United States of America.

Harvard

Yahi N., Fantini J., Baghdiguian S., Mabrouk K., Tamalet C., Rochat H., Van Rietschoten J. and Sabatier J. M. (19950629). SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. : Proceedings of the National Academy of Sciences of the United States of America.

MLA

Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J and Sabatier J M. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. : Proceedings of the National Academy of Sciences of the United States of America. 19950629.